GZMB and myeloid sarcoma: Our studies provide proof of concept that signaling through the Kv1.3 channel is a novel mechanism by which GrB is released and suggest an additional mechanism by which blockade of this channel might be therapeutic in MS and other diseases in which cytoxic T cells damage their target tissue.